Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Schenkein David P					2. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI]						(Ch	elationship deck all applic	able)	Person(s) to Is		
	`	RAPEUTICS IN	(Middle)		s. Date of Earliest Transaction (Month/Day/Year) 05/30/2019						Officer below)	(give title	Other below)	specify		
(Street) SOUTH FRANCI (City)	SCO		94080 (Zip)	4.	If Ame	ndment, I	Date	of Original F	Filed	(Month/Da	ay/Year)	Line	Y Form f	led by One R led by More t	iling (Check A Reporting Pers than One Rep	on
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date) Table II - Derivati				th/Day/Y	ear) i	ZA. Deemo Execution f any Month/Da	Date	Code (Ir 8)	v	Disposed 5) Amount	(A) or	tr. 3, 4 and	5. Amour Securitie Beneficia Owned Reported Transact (Instr. 3 a	s F Ally (I ollowing (I) I ion(s)	. Ownership orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								s, options					Ownea			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		Expiration Date of Set (Month/Day/Year) Under Derive		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	e E	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$19.5	05/30/2019		A		27,245		(1)	0	5/29/2029	Common Stock	27,245	\$0.00	27,245	D	

Explanation of Responses:

1. 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date.

Remarks:

/s/ Tyler Nielsen, by power of <u>attorney</u>

06/03/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.